drugset / Trial / NCT04501796
A Trial of NT-I7 in COVID-19 (SPESELPIS)
Phase 1
Terminated
7 enrolled
NeoImmuneTech
National Institute of Allergy and Infectious Diseases (NIAID) · collabUniversity of Nebraska · collab
RandomizedSequentialQuadruple-blindTreatment
Summary
The main purposes of this study is to determine the following in participants with mild coronavirus disease 2019 (COVID-19): * Safety of a single dose of NT-I7 * The immunological effects of NT-I7 on peripheral lymphocyte counts in COVID-19 patients.
Timeline
- Start
- 2020-11-27
- Primary completion
- 2021-07-21
- Completion
- 2023-02-23
Outcome
Outcome not reported
Stopped (Enrollment): “Study was halted due to lack of patient population resulting in slow enrollment.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NT-I7 | Protein / enzyme biologic | — | Intramuscular |